Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.
HIV-1 variants resistant to small molecule CCR5 inhibitors recognize the inhibitor-CCR5 complex, while also interacting with free CCR5. The most common genetic route to resistance involves sequence changes in the gp120 V3 region, a pathway followed when the primary isolate CC1/85 was cultured with t...
Main Authors: | Reem Berro, Rogier W Sanders, Min Lu, Per J Klasse, John P Moore |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-08-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC2718843?pdf=render |
Similar Items
-
Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5
by: Demarest James F
Published: (2005-12-01) -
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
by: Kuhmann Shawn
Published: (2005-12-01) -
Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry
by: Pooja Singh, et al.
Published: (2022-12-01) -
Clinical use of CCR5 inhibitors in HIV and beyond
by: Gilliam Bruce, et al.
Published: (2010-01-01) -
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.
by: Cleo G Anastassopoulou, et al.
Published: (2007-06-01)